Woods v. Boston Scientific Corp.
Opinion of the Court
SUMMARY ORDER
Defendant-appellant Boston Scientific Corporation (“BSC”) appeals from an order of the district court, entered April 24, 2007, which granted permanent injunctive relief to plaintiffs-appellees Carla Woods and Jeffrey Goldberg (appearing on behalf of the earn-out recipients who formerly held shares in the Bionics Corporation, hereinafter “Bionics”). We assume the parties’ familiarity with the facts, procedural history, and specification of issues on appeal.
We reject BSC’s argument that the district court’s injunction, which enjoins certain acts in derogation of the merger agreement’s dispute resolution process, was premised upon a misconstruction of that agreement. BSC’s assertion that Mann loses his right to appoint his successor should he become “absent” along with his co-CEO by way of termination of both, is without merit. Viewed in the light of the agreement as a whole, these succession provisions are unambiguous: Section 5.04(g)(iii) of the merger agreement grants Alfred Mann (“Mann”) a personal right to select his successor as co-CEO upon his termination. Furthermore, the finding that BSC had attempted to circumvent Section 5.04(g)(i)’s provisions—over which the parties had carefully bargained—is not clearly erroneous. We therefore uphold that portion of the injunction directing BSC to conduct the entire dispute resolution process in good faith from the beginning.
On appeal, BSC presents an additional argument: that the injunction contains a remedy that Bionics had not sought, and which is unconnected to BSC’s contractual obligations. The portion of the injunction that is allegedly excessive is that which commands BSC not to terminate Mann— even in the event that BSC complies with Section 5.04(g)(i) in full—until BSC and Mann can agree on the identity of his successor. Section 1(B) of the permanent injunction provides that “in the event that James Tobin (or his successor as Chief Executive Officer) acts to terminate Mann and/or Grenier as co-chief executive officer after the dispute resolution process of section 5.04(g)(i) of the Merger Agreement is complete, [BSC is enjoined from] taking any action to prevent either Mann and/or Grenier from continuing in the functioning of the duties and responsibilities of their office until Mann and Tobin (or his successor as Chief Executive Officer) mutually
This last concession defeats Bionics argument that we should also uphold this portion of the district court’s order. As this court has held in the past, when fashioning equitable remedies, “[t]he parties’ rights under an unambiguous contract should be fathomed from the terms expressed in the instrument .... [and] [i]n its efforts to preserve the parties’ rights and the status quo, the court must be careful not to alter the terms of the agreement.” Metro. Life Ins. Co. v. RJR Nabisco, Inc., 906 F.2d 884, 889 (2d Cir. 1990). However, we emphasize that our conclusion is based squarely on the reasoning that reformation is a “sharply limited” remedy, see Collins v. Harrison-Bode, 303 F.3d 429, 435 (2d Cir. 2002), which is also discretionary, see generally Restatement (Second) of Contracts § 155, cmt. d (2006).
We also note that this summary order does not seek to circumscribe the district court’s exercise of its broad equitable powers. Springs Mills, Inc. v. Ultracashmere House, Ltd., 724 F.2d 352, 355 (2d Cir. 1983). Accordingly, upon remand the district court remains free to consider appropriate amendments to the permanent injunction as it deems necessary.
Accordingly, the order of the district court is AFFIRMED IN PART and VACATED IN PART, only to the extent that Section 1(B) of the permanent injunction shall be excised, and we REMAND for further proceedings not inconsistent with this order.
Reference
- Full Case Name
- Carla WOODS and Jeffrey Goldberg as Stockholders' Representative and Trustees of the Bionics Trust v. BOSTON SCIENTIFIC CORPORATION
- Cited By
- 1 case
- Status
- Published